Review of venous thromboembolism (VTE) risk, evaluation, and treatment in individuals on estrogen-based gender-affirming hormone therapy
- 14 May 2025
- journal article
- review article
- Published by SAGE Publications in Vascular Medicine
Abstract
Epidemiological studies of transgender women suggest that these individuals experience higher rates of venous thromboembolism than their cisgender peers. Several factors likely increase this risk, including medication use, comorbidities, and social determinants of health. Estrogen-based gender-affirming hormone therapy is critical for helping patients address unwanted secondary sexual characteristics and induce physical changes in accordance with their gender identity. However, the use of estrogen-based gender-affirming hormone therapy may increase the risk of venous thromboembolism. This review article summarizes the current evidence describing venous thromboembolism risk among patients using various forms of estrogen, including transgender and cisgender individuals. The article also discusses strategies for managing venous thromboembolism in patients using estrogen-based gender-affirming hormone therapy and methods to reduce venous thromboembolism risk.Keywords
This publication has 59 references indexed in Scilit:
- Transgender Identity and Suicide Attempts and Mortality in DenmarkJAMA, 2023
- Hormonal therapies and venous thrombosis: Considerations for prevention and managementResearch and Practice in Thrombosis and Haemostasis, 2022
- Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014–2017 BRFSSJournal of Behavioral Medicine, 2019
- Cardiovascular health in transgender peopleReviews in Endocrine and Metabolic Disorders, 2018
- Thrombotic issues in transgender medicine: A reviewAmerican Journal of Hematology, 2017
- Venous ThromboembolismAmerican Journal of Preventive Medicine, 2010
- Estrogen Plus Progestin and Risk of Venous ThrombosisJAMA, 2004
- Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled TrialACC Current Journal Review, 2004
- Noncardiovascular Disease Outcomes During 6.8 Years of Hormone TherapyJAMA, 2002
- Mortality and morbidity in transsexual patients with cross-gender hormone treatmentMetabolism, 1989